IB
IASO Biotherapeutics develops cell therapies targeting specific cancer types by utilizing engineered immune cells to enhance the body’s natural ability to fight tumors. The company aims to improve patient outcomes in oncology by providing more effective treatment options for resistant cancer forms.
Updated 20 months ago
Funding
Funding not disclosed
IBFunding rounds are not available yet.
Founders
Product
Features
- IASO Biotherapeutics develops cell therapies targeting specific cancer types by utilizing engineered immune cells to enhance the body’s natural ability to fight tumors. The company aims to improve patient outcomes in oncology by providing more effective treatment options for resistant cancer forms.